Diverse Functions of KDM5 in Cancer: Transcriptional Repressor or Activator?
Yasuyo OhguchiHiroto OhguchiPublished in: Cancers (2022)
Epigenetic modifications are crucial for chromatin remodeling and transcriptional regulation. Post-translational modifications of histones are epigenetic processes that are fine-tuned by writer and eraser enzymes, and the disorganization of these enzymes alters the cellular state, resulting in human diseases. The KDM5 family is an enzymatic family that removes di- and tri-methyl groups (me2 and me3) from lysine 4 of histone H3 (H3K4), and its dysregulation has been implicated in cancer. Although H3K4me3 is an active chromatin marker, KDM5 proteins serve as not only transcriptional repressors but also transcriptional activators in a demethylase-dependent or -independent manner in different contexts. Notably, KDM5 proteins regulate the H3K4 methylation cycle required for active transcription. Here, we review the recent findings regarding the mechanisms of transcriptional regulation mediated by KDM5 in various contexts, with a focus on cancer, and further shed light on the potential of targeting KDM5 for cancer therapy.
Keyphrases
- gene expression
- transcription factor
- papillary thyroid
- cancer therapy
- dna methylation
- squamous cell
- genome wide
- endothelial cells
- dna damage
- drug delivery
- squamous cell carcinoma
- oxidative stress
- heat shock
- staphylococcus aureus
- escherichia coli
- childhood cancer
- nuclear factor
- amino acid
- toll like receptor
- heat stress